SEC Tracker
Get the app

Corcept Therapeutics CORT

Corcept Therapeutics reports strong Q3 2026 results

Item 2.02 Reports results, Item 7.01 Investor disclosure

Form
8-K
Filed
Importance
Major
  1. Revenue of $340.5 million, up 64% from 2025
  2. Net income of $126.8 million, up from $19.7 million in 2025
  3. Lifyorli revenue grew 92% to $91.4 million
  4. Cash and investments increased to $662.3 million

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Corcept Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

  1. The filing includes a press release with details about the company's financial performance and clinical trial results.
  2. The information in the filing is not considered filed for purposes of the Exchange Act of 1934.
  3. Revenue from Korlym and its authorized generic product was $249.1 million, while Lifyorli revenue was $91.4 million.
  4. The company also reiterated its 2026 revenue guidance of $1.1 to $1.2 billion.
  5. Net income per common share (diluted) was $1.01, up from $0.16 in the third quarter of 2025.
  6. The company's quarterly cash and investments increased by $117.7 million, reaching $662.3 million.
  7. The filing also included results from the BELLA Part A trial for Lifyorli in platinum-resistant ovarian cancer.
  8. Patients who received Lifyorli in combination with nab-paclitaxel and bevacizumab showed clinically meaningful progression-free survival, objective response rate, and overall survival.
  9. The most significant results were observed in patients who had not previously received bevacizumab.

9 of 9 claims matched the filing text.

From the filing

Item 7.01 Regulation FD Disclosure.

Item 7.01 Regulation FD Disclosure.

On November 3, 2026, Corcept Therapeutics Incorporated (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2026 and a corporate update. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference1.

The information in this Item 2.02 and Item 7.01 and the information contained in the press release attached as Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Exchange Act of 19342, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 2.02 and Item 7.01 and the information contained in the press release attached as Exhibit 99.1 is not incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in the filing unless specifically stated so therein.

Item 9.01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibits No. Description

99.1 Press Release of Corcept Therapeutics Incorporated, dated November 3, 2026

104.1 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORCEPT THERAPEUTICS INCORPORATED

Date: November 3, 2026 By: /s/ Atabak Mokari

Name: Atabak Mokari

Title: Chief Financial Officer

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

• Revenue of $340.5 million, a 64 percent increase over the same period in 2025

◦ Korlym ® and authorized generic product revenue of $249.1 million3

◦ Lifyorli ® product revenue of $91.4 million3

• Reiterated 2026 revenue guidance of $1.1 – $1.2 billion4 • Net income of $126.8 million, compared to $19.7 million in third quarter 2025 • Net income per common share (diluted) of $1.01, compared to $0.16 in third quarter 20255

• Quarterly cash and investments increase of $117.7 million, to $662.3 million6

• BELLA Part A trial results in platinum-resistant ovarian cancer7: Patients who received Lifyorli (relacorilant) in addition to nab-paclitaxel and bevacizumab demonstrated clinically meaningful progression-free survival (PFS), objective response rate (ORR) and overall survival (OS)8, with the most pronounced results being in patients earliest in their course of treatment in the platinum-resistant setting, including patients who had no prior treatment with bevacizumab9

REDWOOD CITY, Calif., (November 3, 2026) – Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Repligen RGEN public float $6.0B, Jun 30, 2025
  2. Jazz Pharmaceuticals JAZZ public float $6.3B, Jun 30, 2025
  3. Madrigal Pharmaceuticals MDGL public float $5.6B, Jun 30, 2025
  4. Biomarin Pharmaceutical BMRN public float $6.7B, Jun 30, 2025
  5. Revolution Medicines RVMD public float $6.7B, Jun 30, 2025